A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine operates by activating the mother’s immune system to produce defence proteins, which are then transferred to the developing baby through the placenta. This maternal immunity provides newborns with instant defence from the point of delivery, precisely when they are highly susceptible to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst noting that protection remains possible even if administered later in the third trimester.
- Nearly 85% protection when immunised four weeks before birth
- Maternal antibodies transferred through placenta safeguard newborns from day one
- Protection possible with two-week gap before early delivery
- Vaccination in the third trimester still provides significant protection for infants
Compelling evidence from current research
The efficacy of the RSV vaccine administered during pregnancy has been demonstrated through a extensive research programme carried out throughout England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month timeframe, providing robust and representative evidence of the vaccine’s actual performance. The study’s results have been supported by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The breadth of this investigation provides healthcare professionals and prospective parents with trust in the vaccine’s proven efficacy across diverse populations and circumstances.
The results paint a striking picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV during the study period, with the vast majority being infants whose mothers did not receive the vaccination. This stark contrast underscores the vaccine’s critical role in protecting against serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.
Study design and parameters
The research reviewed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospitalisations. The sizeable sample and thorough nature of the data collection ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology assessed real-world outcomes rather than experimental conditions, providing practical evidence of how the vaccine performs when given across different clinical contexts and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and the dangers
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection triggers deep inflammation in the lungs and airways, making it dangerously difficult for affected infants to feed and breathe adequately. Parents commonly see their babies struggling visibly, their chests rising whilst they try to pull sufficient oxygen into their weakened respiratory system. Whilst most infants recover with clinical support, a limited though important number die from RSV complications each year, making vaccination as prevention a essential public health imperative for defending the most vulnerable and youngest members of society.
- RSV triggers inflammation in lungs, causing serious respiratory problems in babies
- Half of all infants contract the infection in their first few months of life
- Symptoms vary between mild colds to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV each year
- A small number of infants succumb to RSV related complications annually in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have emphasised the value of pregnant women receiving their jab at the best time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing matters greatly for guaranteeing newborns receive the strongest possible immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery provides nearly 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy forward to increase the antibodies passed to their babies through the placenta.
The messaging from health authorities stays clear: pregnant women ought to prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This flexible approach recognises the practical demands of pregnancy whilst ensuring strong safeguarding for vulnerable newborns during their earliest and most vulnerable period when RSV represents the highest danger of severe infection.
Regional differences in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Some areas have attained higher vaccination coverage among eligible pregnant women, whilst others remain focused to increase awareness and access to the jab. These regional differences demonstrate variations in medical facilities, communication strategies, and local engagement efforts, though the overall statistics shows robust and reliable protection regardless of geographical location.
- NHS trusts deploying diverse outreach initiatives to connect with women during pregnancy
- Inconsistencies across regions in immunisation take-up in different parts of England necessitate strategic intervention
- Local healthcare systems tailoring initiatives to align with community needs and circumstances
Practical implications and parent viewpoints
The vaccine’s impressive effectiveness provides tangible benefits for families across the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the launch of this safeguarding intervention, the 80% drop in admissions means thousands of infants spared from serious illness. Parents no longer face the upsetting situation of seeing their babies labour to breathe or struggle to eat, symptoms that mark serious RSV disease. The vaccine has markedly changed the landscape of neonatal respiratory health, giving expectant mothers a active means to safeguard their youngest infants during those vital initial period.
For families like that of Malachi, whose acute RSV infection caused profound brain damage, the vaccine’s availability carries profound emotional significance. His mother’s support of the jab emphasises the transformative consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to pregnant women navigating their late pregnancy, transforming what was once an predictable seasonal threat into a controllable health concern.